Akoya Biosciences Inc

Akoya Biosciences, Inc. is a life sciences technology company delivering spatial biology solutions focused on transforming discovery and clinical research. The company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and treatment response. Akoya offers two distinct solutions, the CODEX and Phenoptics platforms, to serve the diverse needs of researchers across discovery, translational and clinical research. The company was founded by Garry Nolan, Yury Goltsev and Nikolay Samusik in 2015 and is headquartered in Marlborough, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Akoya Biosciences achieves record revenue, eyes strategic growth initiatives

Akoya Biosciences reported impressive financial performance and outlined strategic priorities for 2023, focusing on revenue growth and operational enhancements.
While facing challenges like anemic reagent revenue and increasing expenses, the company remains optimistic about its position for growth and market opportunities.
With a strong emphasis on partnerships, product innovation, and revenue diversification, Akoya is poised to leverage its strengths and navigate challenges for sustained success.

Akoya Biosciences reports record Q1 revenue and eyes sustained growth

Akoya Biosciences' Q1 performance reflects strong revenue growth and strategic focus on sustained high growth.
The company aims for cash flow positivity by 2025 through targeted spending and revenue growth.
Challenges include successful Fusion 2.0 upgrades and driving reagent growth, balanced with maintaining high performance.
Opportunities lie in upgrading customers, partnerships, and innovative solutions driving revenue growth.

Akoya Biosciences reports record Q2 revenue and strategic growth plans

Akoya Biosciences excelled in Q2 2023 with record revenue and system placements, showcasing strength in spatial biology solutions.
The company's focus on reagent revenue growth, system upgrades, and revenue guidance highlights a strategic path for future growth.
While facing challenges in gross margins and adoption methodologies, Akoya's investments and opportunities position it well for continued success.

Akoya Biosciences excels in Q3, eyes sustained growth and efficiency

Akoya Biosciences delivered a standout performance in Q3 2023, marked by record revenue and gross profit, supported by a robust install base and strategic initiatives.
The company's strengths lie in workflow efficiency enhancements, strong gross margins, and a clear growth strategy through services and partnerships.
Challenges include achieving cash flow positivity, sustaining margins, and driving adoption of new solutions, while opportunities abound in genomics, partnerships, and market expansion.
Overall, Akoya's focus on innovation, efficiency, and market positioning sets a solid foundation for continued growth and financial success.

Akoya Biosciences reports record-breaking revenue and strategic partnerships for growth

Akoya Biosciences delivered impressive financial performance in Q4 2023, showcasing revenue growth, cost management, and strategic investments. While facing challenges from macro pressures and underperformance in certain regions, the company remains focused on achieving cash flow breakeven by 2024. Akoya's strengths in partnerships and product enhancements position them well for continued growth and margin expansion.

Akoya Biosciences reports Q1 revenue decline but eyes growth opportunities

Akoya Biosciences faced revenue decline in Q1 due to weak instrument placements but saw growth in reagent and services revenue, aiming for breakeven by year-end.
The company updated its 2024 revenue outlook, expecting a measured recovery and sustained growth, with opportunities in partnerships and margin improvement initiatives.
Challenges include academic budget assumptions impacting revenue guidance and increasing outsourcing to CROs affecting reagent growth opportunities.
Despite challenges, Akoya's strengths lie in strong reagent revenue growth, strategic partnerships, and potential for achieving higher gross margins in the future.

Akoya Biosciences reports strong Q2 revenue growth and eyes market expansion

Akoya Biosciences demonstrated robust revenue growth in Q2 2024, driven by strong performance across instrument, reagent, and service segments.
While facing challenges in revenue guidance adjustments and delayed impact from NMPA approval in China, Akoya's strategic initiatives and product strengths offer promising opportunities for future growth.
Overall, Akoya's focus on financial goals, product innovation, and market expansion sets a positive trajectory for the company's performance and competitiveness in the biotech sector.

Akoya Biosciences reports Q3 revenue dip, focuses on strategic growth

Akoya Biosciences faced revenue challenges in Q3 2024 but showed operational improvements and strategic advancements.
The company is focused on enhancing efficiency, expanding product offerings, and leveraging partnerships for growth.
While navigating competitive pressures and cash flow concerns, Akoya Biosciences aims for sustainable profitability and market leadership.
Strategic initiatives, stable gross margins, and a strong leadership team position Akoya Biosciences for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Akoya (AKYA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Strength Seen in Akoya (AKYA): Can Its 7.4% Jump Turn into More Strength?

PhenoCycler®-Fusion system selected as the Centre's platform technology for advanced spatial biology studies PhenoCycler®-Fusion system selected as the Centre's platform technology for advanced spatial biology studies

Akoya Biosciences' Technology Enables Queensland Spatial Biology Centre to Revolutionize the Diagnosis and Treatment of Cancer and Other Diseases

Leading immunotherapy and immunobiology experts will offer strategic direction and expertise in translational, clinical, and diagnostic applications of Akoya's spatial biology solutions Leading immunotherapy and immunobiology experts will offer strategic direction and expertise in translational, clinical, and diagnostic applications of Akoya's spatial biology solutions

Akoya Biosciences Announces that Garry Nolan, Ph.D., James Allison, Ph.D.

AC Immune

Anavex Life Sciences

Getaround Inc

GRIFFIN RLTY TRUST INC

Anavex Life Sciences (AVXL), Peakstone Realty Trust (PKST), AC Immune (ACIU), Getaround (GETR) and Akoya Biosciences (AKYA) could be solid picks to play the January Effect.

5 Small-Cap Stocks to Play the January Effect

Alpha Tau Medical

Trupanion

AKYA, DRTS and TRUP made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 8, 2024.

Best Momentum Stocks to Buy for January 8th

Quantasing Group Ltd

Tim SA

TIMB, AKYA, DRTS, TRUP and QSG have been added to the Zacks Rank #1 (Strong Buy) List on January 8, 2024.

New Strong Buy Stocks for January 8th

MaxFuse enables matching and integration of datasets from spatial proteomics, spatial transcriptomics, single-cell sequencing, or other modalities

Akoya Biosciences Deploys the MaxFuse Algorithm Co-Developed by Dr. Garry Nolan and His Laboratory at Stanford University for Multiomic Integration of Spatial and Single-cell Data on the Enable Medicine Platform

MARLBOROUGH, Mass., Jan. 07, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced preliminary unaudited revenue for the fourth quarter and full year ended December 31, 2023, and projected year end 2023 cash, cash equivalents, and restricted cash balance, which remain subject to quarter end closing adjustments and are also unaudited.

Akoya Biosciences Announces Preliminary Financial Results for the Fourth Quarter and Full Year 2023 and Provides 2024 Outlook

The Thermo Fisher Scientific ViewRNA technology combined with Akoya's market leading spatial biology solutions will enable rapid, whole-slide imaging of RNA and protein biomarkers The Thermo Fisher Scientific ViewRNA technology combined with Akoya's market leading spatial biology solutions will enable rapid, whole-slide imaging of RNA and protein biomarkers

Akoya Biosciences and Thermo Fisher Scientific Announce a License and Distribution Agreement to Deliver Spatial Multiomics Workflow

Akoya Biosciences (AKYA) has seen solid earnings estimate revision activity over the past two months, and belongs to a strong industry as well.

How Akoya Biosciences (AKYA) Stock Stands Out in a Strong Industry

The average of price targets set by Wall Street analysts indicates a potential upside of 86% in Akoya (AKYA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

How Much Upside is Left in Akoya (AKYA)? Wall Street Analysts Think 86%

MARLBOROUGH, Mass., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will be participating in the 42nd Annual J.P. Morgan Healthcare Conference.

Akoya to Participate at 42nd Annual J.P. Morgan Healthcare Conference

Akoya Biosciences has seen a significant decline in its stock price but has recently bounced back by 55%. The company has shown consistent revenue growth over the past four years, with a projected revenue of up to $98.0 million for 2023. Akoya has formed a partnership with Agilent, potentially leading to a merger, and has achieved gross profits of 60% on its revenue stream.

Akoya Biosciences: 2024 Could Be The Year To Own Their Stock

Akoya Biosciences, Inc. (NASDAQ:AKYA ) Q3 2023 Earnings Conference Call November 8, 2023 5:00 PM ET Company Participants Priyam Shah - Head of Investor Relations Brian McKelligon - Chief Executive Officer Johnny Ek - Chief Financial Officer Conference Call Participants Edmund Tu - Morgan Stanley Kyle Mikson - Canaccord Genuity Timothy Chiang - Capital One Mason Carrico - Stephens Inc. Operator Good day, ladies and gentlemen, and thank you for standing by. Welcome to the Akoya Biosciences Incorporated Third Quarter 2023 Earnings Conference Call.

Akoya Biosciences, Inc. (AKYA) Q3 2023 Earnings Call Transcript

Q3 2023 revenue $25.2 million, 34% y/y growth Reiterating FY 2023 revenue guidance range of $95-98 million

Akoya Reports Record Revenue in the Third Quarter of 2023 and Reiterates Full Year 2023 Revenue Guidance

MARLBOROUGH, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that Company management will be participating in three upcoming investor conferences.

Akoya to Participate at Three Upcoming Investor Conferences

Spatial Biology 2.0 solutions enable discovery and translational workflows at an unprecedented speed and scale Global network of CROs providing Akoya's spatial phenotyping solutions will also exhibit at SITC MARLBOROUGH, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences Inc., (Nasdaq: AKYA) The Spatial Biology Company®, today announced that it will be showcasing its latest Spatial Biology 2.0 solutions and ultrahigh-plex (100+ protein biomarkers) spatial phenotyping data at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting, being held in San Diego, California, November 1-5, 2023.

Akoya Biosciences to Showcase New Spatial Biology 2.0 Solutions and Spatial Phenotyping Data at SITC 2023

MARLBOROUGH, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that researchers from Akoya Biosciences and The University of Queensland's Frazer Institute have comprehensively mapped the spatial proteome of head and neck squamous cell carcinoma (HNSCC) using ultrahigh-plex spatial phenotyping. Spatial phenotyping consists of whole-slide imaging of tissue sections at single-cell resolution to visualize and quantitate biomarker expression and reveal how cells interact and organize across the entire tissue landscape.

Akoya Biosciences Announces Peer-Reviewed Publication Using Ultrahigh-Plex Spatial Phenotyping of Head and Neck Cancer to Identify Distinct Immune and Metabolic Signatures

MARLBOROUGH, Mass., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the third quarter of 2023 after the market close on November 8th, 2023. Company management will host a conference call to discuss financial results at 5:00 p.m. ET.

Akoya to Report Third Quarter 2023 Financial Results on November 8th, 2023

MARLBOROUGH, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today highlighted the industry-leading scale and speed in whole-slide, spatial biology workflows enabled by the recently launched PhenoCycler®-Fusion 2.0 and PhenoImager® HT 2.0 platform upgrades. Enhancements to the PhenoCycler-Fusion 2.0 System allow customers to process twice as many samples per week, making it the highest throughput spatial discovery platform on the market. The PhenoImager 2.0 platform delivers a 5x workflow improvement by enabling rapid real-time image analysis directly on the HT instrument. With an unprecedented ability to perform whole-slide spatial biology at scale, Akoya's customers can accelerate progress towards new discoveries, identification of clinically relevant biomarkers, and development of novel spatial signatures.

Akoya Biosciences Sets a New Standard for Scaling Spatial Biology with the Launch of 2.0 Platforms

Akoya Biosciences, Inc. (NASDAQ:AKYA ) Q2 2023 Earnings Conference Call August 7, 2023 5:00 PM ET Company Participants Priyam Shah - IR Brian McKelligon - CEO John Ek - CFO Conference Call Participants Kyle Mikson - Canaccord Genuity Lucas Baranowski - UBS Rachel Vatnsdal - JPMorgan Chase Mark Massaro - BTIG Edmund Tu - Morgan Stanley Tim Chiang - Capital One David Westenberg - Piper Sandler Mason Carrico - Stephens Inc. Operator Good day and welcome to the Akoya Biosciences Second Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode.

Akoya Biosciences, Inc. (AKYA) Q2 2023 Earnings Call Transcript

Akoya Biosciences (AKYA) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $0.47 per share a year ago.

Akoya Biosciences (AKYA) Reports Q2 Loss, Tops Revenue Estimates

Q2 2023 revenue $23.5 million, 31% y/y growth Reiterating FY 2023 revenue guidance range of $95-98 million

Akoya Reports Record Revenue in the Second Quarter of 2023 and Reiterates Full Year 2023 Revenue Guidance

MARLBOROUGH, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences , Inc. (Nasqad: AKYA)(“Akoya), The Spatial Biology Company®, today announced a momentous achievement - publication of the 1,000th peer-reviewed article citing use of the company's technology, the largest publication volume in the industry. Approximately 80% of these articles have been published in the last 2.5 years, reflecting the exponential growth in adoption of Akoya's solutions.

Akoya Biosciences Announces Milestone of 1,000 Peer-Reviewed Publications Citing Use of its Spatial Biology Technologies

American Assets

American Vanguard

Cannae Hlds

Domo

Enviva Partners

National Vision Hlds

Globalstar

Heartland Express

I3 Verticals

MillerKnoll

PacWest Bancorp

Pebblebrook Hotel Trust

Pulse Biosciences

B. Riley Financial

Skillz

ACELYRIN Inc

SPDR S&P 500 ETF Trust

Stellar Bancorp Inc

StepStone Group

Washington Federal

Zumiez

After covering second-quarter corporate insider activity among mid-cap and large-caps, today's article will cover on the most interesting insider purchases for small-cap companies. Corporate insiders at American Assets Trust, National Vision, Skillz, Enviva, Heartland Express, and Zumiez have been buying significant amounts of shares, signaling confidence in their respective companies. Other notable insider activity among small-cap stocks includes B. Riley Financial, Cannae Holdings, i3 Verticals, whose CEOs have bought million worth of stock in the second quarter.

News for Akoya Biosciences Inc Stock (AKYA)